Clinical Trials Logo

Filter by:
NCT ID: NCT00294567 Completed - Hypertension Clinical Trials

Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)

Start date: December 2005
Phase: Phase 4
Study type: Interventional

In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine besilate (Norvasc or Amlodin).

NCT ID: NCT00292708 Completed - Colorectal Surgery Clinical Trials

Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery

Start date: May 2004
Phase: Phase 3
Study type: Interventional

To determine the optimal prophylactic antibiotics administration method in elective colorectal surgery

NCT ID: NCT00292448 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The objective of this trial is to compare the efficacy and the safety of Ba 679 BR Respimat 5 ug once daily to tiotropium inhalation capsule 18 ug (Spiriva inhalation capsule) in a crossover study of 4-week treatment periods in patients with COPD.

NCT ID: NCT00291668 Completed - Crohn's Disease Clinical Trials

Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

Start date: March 2, 2006
Phase: Phase 2
Study type: Interventional

This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.

NCT ID: NCT00291473 Completed - Breast Cancer Clinical Trials

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

Start date: July 2005
Phase: Phase 1
Study type: Interventional

Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens. Nine patients will be enrolled, who are refractory to standard therapies for cancer or at high risk to relapse. CHP-HER2 and CHP-NY-ESO-1 are subcutaneously given on bimonthly basis, together with OK-432(Picibanil) as an immunoadjuvant. Six doses will be given. Toxicity profiles will be monitored, and antigen specific humoral anad T cell responses will be described.

NCT ID: NCT00291005 Completed - Prostatic Neoplasms Clinical Trials

PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone

Start date: August 2004
Phase: Phase 2
Study type: Interventional

- To evaluate the overall tumor response rate in subjects with metastatic hormone refractory prostate cancer - To evaluate PSA (tumor marker) response rate - To evaluate safety

NCT ID: NCT00290992 Completed - Clinical trials for Nutritional and Metabolic Diseases

Rasburicase for Hyperuricemia

Start date: June 2005
Phase: Phase 2
Study type: Interventional

Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma uric acid concentration. Secondary: To investigate the safety in this population and anti-SR29142 antibodies, anti-SCP antibodies, and pharmacokinetic parameters.

NCT ID: NCT00290979 Completed - Clinical trials for Diabetes Mellitus, Type 1

Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus

Start date: December 2004
Phase: Phase 3
Study type: Interventional

- To evaluate non-inferiority in the efficacy of HMR1964 as compared with Insulin lispro in terms of the change in HbA1C from baseline to endpoint. - To compare the safety of HMR1964 with insulin lispro.

NCT ID: NCT00290927 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus

Start date: December 2003
Phase: Phase 3
Study type: Interventional

- To evaluate the superiority in the efficacy of HMR1964 and OHA combination therapy as compared with OHA therapy. - To evaluate the superiority in the efficacy of HMR1964 mono-therapy as compared with OHA therapy. - To evaluate the safety of HMR1964.

NCT ID: NCT00287768 Completed - Gastric Cancer Clinical Trials

Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer

Start date: March 2006
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare median overall survival of the test arm (docetaxel and S-1) to the control arm (S-1 only) in subjects with advanced or recurrent gastric cancer.